Comparisons of alloreactive potential of clinical hematopoietic grafts

Background. We sought to compare the immunoreactive potential of human cord blood (CB) versus normal adult bone marrow (BM) versus mobilized blood (pe ripheral blood stem cells; PBSC) from cancer patients. Methods. Forty mice were randomized to receive a range of doses of T cell-r eplete cell preparations from one of the above three cell. sources. Twenty- eight control mice underwent transplantation with T cell-depleted cells. Mi ce were observed for 60 days for the development of fatal xenogeneic graft- versus-host disease-like syndrome (GVHDLS). Results. For the mice that had received T cell-replete grafts of CB or BM o r PBSC, the duration of GVHDLS-free survival of the chimeras was inversely proportional to the number of T cells transplanted. After adjustment for th e number of T cells transplanted, the relative hazard of developing fatal G VHDLS was 62-fold higher for PBSC and 210-fold higher for BM as compared wi th CB. Flow cytometric and histologic analyses of selected chimeras that di ed of GVHDLS showed extensive proliferation of human T cells in multiple or gans. In contrast, mice that survived to day 60 were engrafted with human m yeloid and B lymphoid cells. Conclusions. The immunoreactive potential, as measured by this in vivo assa y, differed among clinical grafts: BM > PBSC > CB.